TAKEDA PHARMACEUTICALS AMERICA INC

BUD · Budget/Appropriations

FY 2025 Budget Resolution - Pharmaceutical Related Provisions

MMM · Medicare/Medicaid

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Proposals related to amending the protected classes in Medicare Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on spillover related to the IRA Discussions on reforming the Inflation Reduction Act Discussions on treatment of small molecule drugs related to Inflation Reduction Act Discussions on treatment of small molecule drugs related to Inflation Reduction Act H.R.1 492, S. 832, EPIC Act of 2025, All Pharmaceutical Related Provisions H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act

Literal federal measure citations: H.R.1, S. 832, H.R. 946

HCR · Health Issues

Clarify or reform the 340B program Issues related to patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Issues related to rare disease diagnosis and access to care Issues related to Pharmacy Benefit Managers (PBMs) H.R. 1476, S. 694, PLASMA Act

Literal federal measure citations: H.R. 1476, S. 694

TAX · Taxation/Internal Revenue Code

Administration's Global Tax Proposal General issues around 2025 Reconciliation/Inbound Concerns

TRD · Trade (domestic/foreign)

Issues related to proposed Tariffs - all pharmaceutical related provisions

DEF · Defense

Discussions around Supply Chain implications